f biological targeted drugs can ensure that the patient's condition is as standardized as possible.

Song Yuanlin, director of the Department of Respiratory and Critical Care Medicine at Zhongshan Hospital Affiliated to Fudan University, said that targeted biological therapy is a very good treatment plan in the field of asthma in recent years. Eosinophils are reduced by inhibiting the release of some inflammatory factors in the respiratory tract. Treatment through this targeting some of its core pathogenesis and key targets can achieve very good results.

The "Guidelines for the Prevention and Treatment of Bronchial Asthma (2024 Edition)" points out that if some patients in the clinical control period do not have acute asthma attacks and other symptoms within one year after biological targeted drug treatment or other anti-asthma treatment, and their lung function is basically normal, and they do not need oral glucocorticoids, it can be called clinical cure.

Zhang Min, director of the Department of Respiratory and Critical Care Medicine at the First People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, told reporters, "There has been a very leap in the development of asthma recently. In fact, it is a breakthrough in many of our biological targeted treatments, which will be more accurate. The control of our asthma is an acute attack, especially a moderate to severe acute attack, which can reduce the range of 70% to 80%. Through our current diagnosis and treatment methods and through our current management capabilities, some patients can fully achieve clinical cure."

[Editor in charge: Wu Qilong]